Fraunhofer Life Science Symposium, Leipzig, Germany

The Fraunhofer Institute for Cell Therapy and Immunology will hold the third Life Science Symposium in Leipzig, Germany, on 24 and 25 October. This time, the symposium will be dedicated to ischaemia and regeneration with a focus on stroke, cardiac infarction and circulation disorders. Additional sessions will include the topic of stem cells in ischaemic diseases.

More specifically, keynote speeches and presentations will address the following topics:

  • clinical indication and long-term outcome of cardiac stem-cell therapy;
  • regeneration in cerebral ischaemia;
  • the potential of cell therapy with human embryonic stem cells in stroke;
  • regeneration of circulation disorders;
  • the therapeutic potential of bone marrow cells in the failing heart;
  • stem cells in ischaemic diseases;
  • process development for cell-based therapies in ischaemic diseases;
  • apart from bone marrow - application of stem cell products in clinical trials;
  • monitoring and imaging in ischaemic diseases;
  • imaging of pathobiology in stroke: from mouse to man.

In addition to international scientists presenting their latest findings, there will be an industry exhibition.

For further information, please visit:
http://www.fs-leipzig.com/

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...